Radiation Oncology Journal

  • 제26권4호
  • /
  • Pages.213-221
  • /
  • 2008
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

직장암에 수술 전 항암화학방사선 동시 병용요법 후 종양의 병리학적 반응에 영향을 주는 임상적 예측 인자

Clinical Factors Predicting the Pathologic Tumor Response after Preoperative Concurrent Chemoradiotherapy for Rectal Cancer

  • 이지혜 (이화여자대학교 의학전문대학원 방사선종양학교실) ;
  • 이경자 (이화여자대학교 의학전문대학원 방사선종양학교실)
  • Lee, Ji-Hae (Department of Radiation Oncology, School of Medicine, Ewha Womans University) ;
  • Lee, Kyung-Ja (Department of Radiation Oncology, School of Medicine, Ewha Womans University)
  • 발행 : 2008.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 직장암에 수술 전 항암화학요법과 방사선치료를 동시에 병용시행한 후 완치절제술 후 병리학적 완전관해율과 종양 병기 하향률에 영향을 주는 예측인자를 후향적으로 분석하여 환자에 따른 맞춤치료의 가능성을 알기 위하여 본 연구를 시도하였다. 대상 및 방법: 2000년 5월부터 2008년 3월까지 국소적으로 진행된 직장암으로 진단받고 원격전이가 없는 환자 39명을 대상으로 수술 전 항암화학요법과 골반강에 방사선치료 50.4 Gy ($45{\sim}59.4\;Gy$)를 시행한 후 완치적 수술후 절제된 조직을 병리학적으로 관찰하여 완전관해율과 종양 및 림프절의 병기하향률을 측정하였다. 항암화학요법은 39명 중 38명은 방사선치료 1주와 5주에 각각 1주간 5-fluorouracil과 leucovorin을 연속적으로 정맥 주입하였으며 1명은 방사선치료기간 중 하루에 2회 capecitabine를 복용하였다. 결 과: 병리학적 완전관해를 보인 환자는 39명 중 12명(31%), 종양-병기하향을 보인 환자는 24명(63%)이었으며 임상적으로 림프절이 양성인 환자 28명 중 12명은(43%) 병리학적으로 하향되었으며 2명은 임상적으로 림프절이 음성이었으나 병리학적으로 양성을 보였다. 단변량분석에 의하면 종양의 둘레범위가 직장의 50% 미만(p=0.031), 종양의 길이가 5 cm 미만(p=0.004), 치료 후 CEA 수치가 3.0 mg/mL 이하(p=0.015)인 환자에서 병리학적 완전관해율이 높았다. 또한 선암(p=0.045), 방사선량이 50 Gy 이상(p=0.021)인 환자에서 병기-하향률이 높았고, 방사선 치료 기간이 42일 이하인(p=0.018)환자에서 림프절-병기하향률이 높았다. 다변량분석에 의하면 종양의 둘레범위가 50% 미만(HR 0.150; p=0.028), 종양의 길이가 5 cm 미만인(HR 0.084; p=0.005) 환자에서 통계학적으로 유의하게 병리학적 완전관해율이 높았으며, 방사선량이 50 Gy 이상 높은 경우(HR 0.115; p=0.025) 종양-병기하향률이 높았고 방사선치료 기간이 42일 이하인(HR 0.028; p=0.010) 경우 림프절-병기하향률이 높았다. 병리학적 완전관해에 영향을 주는 예측인자는 종양의 둘레범위와 종양의 길이이었으며, 종양-병리하향에 영향을 주는 예측인자는 방사선량, 림프절-병기하향에 영향을 주는 예측인자는 방사선치료 기간이었다. 이러한 예측인자를 파악함으로써 환자의 치료결과를 예측할 수 있으며 위험인자가 있는 환자에 좀 더 적극적인 치료계획을 설정하는 데 도움이 될 것으로 생각한다.

Purpose: The objective of this retrospective study was to identify predictive factors for the complete pathologic response and tumor downstaging after preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. Materials and Methods: Between the years 2000 and 2008, 39 patients with newly diagnosed rectal cancer without prior evidence of distant metastasis received preoperative concurrent chemoradiotherapy followed by surgery. The median radiation dose was 50.4 Gy (range, $45{\sim}59.4\;Gy$)). Thirty-eight patients received concurrent infusional 5-fluorouracil and leucovorin, while one patient received oral capecitabine twice daily during radiotherapy. Results: A complete pathologic response (CR) was demonstrated in 12 of 39 patients (31%), while T-downstaging was observed in 24 of 39 patients (63%). N-downstaging was observed in 18 of 28 patients (64%), with a positive node in the CT scan or ultrasound. Two patients with clinical negative nodes were observed in surgical specimens. The results from a univariate analysis indicated that the tumor circumferential extent was less than 50% (p=0.031). Moreover, the length of the tumor was less than 5 cm (p=0.004), while the post-treatment carcinoembryonic antigen (CEA) levels were less than or equal to 3.0 ng/mL (p=0.015) and were significantly associated with high pathologic CR rates. The univariate analysis also indicated that the adenocarcinoma (p=0.045) and radiation dose greater than or equal to 50 Gy (p=0.021) were significantly associated with high T-downstaging, while a radiotherapy duration of less than or equal to 42 days (p=0.018) was significantly associated with N-downstaging. The results from the multivariate analysis indicated that the lesser circumferential extent of the tumor (hazard ratio [HR] 0.150; p=0.028) and shorter tumor length (HR, 0.084; p=0.005) independently predicted a higher pathologic CR. The multivariate analysis also indicated that a higher radiation dose was significantly associated with higher T-downstaging (HR, 0.115; p=0.025), while the shorter duration of radiotherapy was significantly associated with higher N-downstaging (HR, 0.028; p=0.010). Conclusion: The circumferential extent of the tumor and its length was a predictor for the pathologic CR, while radiation dose and duration of radiotherapy were predictors for tumor downstaging. Hence, these factors may be used to predict outcomes for patients and to develop further treatment guidelines for high-risk patients.

키워드

참고문헌

  1. Gastrointestinal Tumor Study Group. Prolongation of the disease- free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-1472 https://doi.org/10.1056/NEJM198506063122301
  2. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracial with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992;10:549-557 https://doi.org/10.1200/JCO.1992.10.4.549
  3. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-715 https://doi.org/10.1056/NEJM199103143241101
  4. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507 https://doi.org/10.1056/NEJM199408253310803
  5. Minsky BD, Cohen AM, Kemney N, et al. Combined modality therapy for rectal cancer; decreased acute toxicity with the preoperative approach. J Clin Oncol 1992;10:1218-1224 https://doi.org/10.1200/JCO.1992.10.8.1218
  6. Choi SG, Kim SS, Bae HS. Results of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. J Korean Soc Ther Radiol Oncol 2007;25:34-42
  7. Minsky BD, Cohen AM, Enker WE, Paty P. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys 1995;31:553-559 https://doi.org/10.1016/0360-3016(94)00375-U
  8. Janjan NA, Khoo VS, Abbrnzzese J, et al. Tumor downstaging and sphincter preservation in locally advanced rectal cancer: the M.D. Anderson Cancer Center Experience. Int J Radiat Oncol Biol Phys 1999;44:1007-1038
  9. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740 https://doi.org/10.1056/NEJMoa040694
  10. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorcidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005;23:5620-5627 https://doi.org/10.1200/JCO.2005.02.113
  11. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-760 https://doi.org/10.1016/j.ijrobp.2004.11.017
  12. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who received preoperative chemoradiation for rectal cancer. Cancer 2007;109:1750-1755 https://doi.org/10.1002/cncr.22625
  13. Garcia-Aguilar J, Hermandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patient treated by mesorectal excision. Dis Colon Rectum 2003;46:298-304 https://doi.org/10.1007/s10350-004-6545-x
  14. Kaminsky-Forrett MC, Conroy T, Luporsi E, et al. Tlevel downstaging and complete pathologic regression after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002;45:815-903
  15. Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade of regression (GR) in patient with rectal carcinoma treated properative radiochemotherapy. Int J Colorectal Dis. 2006;21:645-651 https://doi.org/10.1007/s00384-005-0061-x
  16. Roodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradio-therapy for rectal cancer. J Clin Oncol 2005;23:8688-8696 https://doi.org/10.1200/JCO.2005.02.1329
  17. Bouzourene H, Bosmen FT, seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patient with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94: 1121-1130 https://doi.org/10.1002/cncr.10327
  18. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002;53:664-674 https://doi.org/10.1016/S0360-3016(02)02764-5
  19. Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000;46:883-888 https://doi.org/10.1016/S0360-3016(99)00486-1
  20. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004;47:1798-1807 https://doi.org/10.1007/s10350-004-0681-1
  21. Janjan NA, Abbruzzese J. Pazdau R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 1995;51:153-160 https://doi.org/10.1016/S0167-8140(99)00054-7
  22. Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2007;69:1167-1172 https://doi.org/10.1016/j.ijrobp.2007.04.047
  23. Park YA, Sohn SK, Seong J, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006;93:145-150 https://doi.org/10.1002/jso.20320
  24. Sanghera P, Wong WY, McConkey CC, Geh JI, Hartley A. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncology 2008; 20:176-183 https://doi.org/10.1016/j.clon.2007.11.013
  25. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279-286 https://doi.org/10.1007/s10350-003-0062-1
  26. Giratt J, Eraso A, Armengol M, et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patient treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1460-1465 https://doi.org/10.1016/S0360-3016(02)03752-5
  27. Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-3401 https://doi.org/10.1200/JCO.2003.07.077
  28. Smith FM, Reynolds JV, Kay EW, et al. Cox-2 overexpression in pretreatment biopsies predicts response of rectal cancer to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 2006;64:466-472 https://doi.org/10.1016/j.ijrobp.2005.07.961
  29. Ghadimi BM, Grade M, Difilippaontonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinoma to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-1838 https://doi.org/10.1200/JCO.2005.00.406
  30. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum with final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564-572 https://doi.org/10.1007/BF02049863
  31. Stockholm Colorectal Cancer Study Group. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol 1996;3:423-430 https://doi.org/10.1007/BF02305759
  32. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-987 https://doi.org/10.1056/NEJM199704033361402
  33. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomized trials. Lancet 2001;358:1291-1304 https://doi.org/10.1016/S0140-6736(01)06409-1
  34. Gerad JP, Conroy T, Bonnetain F, et al. Preoperatuve radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancer: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625 https://doi.org/10.1200/JCO.2006.06.7629
  35. Bosset JF, Collete L, Calaise G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123 https://doi.org/10.1056/NEJMoa060829
  36. Boulis-Wassif S, Gerad A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil followed by radical surgery. Trial of the europena orgniazation on resrarch and treatment of cancer gastrointestinal tract cancer cooperative group. Cancer 1984;53:1811-1818 https://doi.org/10.1002/1097-0142(19840501)53:9<1811::AID-CNCR2820530902>3.0.CO;2-H
  37. Grann A, Minsky BD, Cohen AM, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin and concurrent radiation therapy for clinically resectalbe T3 rectal cancer. Dis Colon Rectum 1997;40:515-522 https://doi.org/10.1007/BF02055370
  38. Chan A, Wong A, Langevin J, Khoo R. Preoperative concurrent 5-fluorouracil infusion, mitomycin-C and pelvic radiation therapy in tethered and fixed rectal carcinoma. Int J Radiat Oncol Biol Phys 1993;25:791-799 https://doi.org/10.1016/0360-3016(93)90307-H
  39. Gerad JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiatiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R004 phase II trial. J Clin Oncol 2003;21:1119-1124 https://doi.org/10.1200/JCO.2003.10.045
  40. Moertel C, Childs D, O'Fallon J. Combined 5-FU and radiation therapy as a surgical adjuvant for poor prognostic gastric cancer. J Clin Oncol 1984;2:1249-1254 https://doi.org/10.1200/JCO.1984.2.11.1249
  41. John M, Pajak T, Flam M, et al. Dose acceleration in chemoradiation for anal cancer: preliminary results of RTOG 9208. Cancer J Sci Am 1996;2:205-211
  42. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002;45:895-903 https://doi.org/10.1007/s10350-004-6325-7
  43. Kaminsky-Forett MC, Conroy T, Luporsi E, et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer: Int J Radiat Oncol Biol Phys 1998;42:935-941 https://doi.org/10.1016/S0360-3016(98)00345-9
  44. Wheeler JM, Warren BF, Jones AC, Mortensen NJ. Preoperative radiotherapy for rectal cancer: implications for surgeons, pathologists and radiologists. Br J Surg 199;86:1108-1120 https://doi.org/10.1046/j.1365-2168.1999.01209.x
  45. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Coloretal Dis 1997;12:19-23 https://doi.org/10.1007/s003840050072
  46. Ahmed NR, Nagle DA, Topham A. Pathologic complete response predicts long-term survival following preoperative radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 1997;39(Suppl):284
  47. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396-2402 https://doi.org/10.1200/JCO.1999.17.8.2396
  48. Willett CG, Warland G, Hagan MP, et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995;13:1417-1424 https://doi.org/10.1200/JCO.1995.13.6.1417
  49. Esposito G, Pucciarelli S, Alaggio R, et al. p27Kip1 is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-338 https://doi.org/10.1007/s10434-001-0311-2
  50. Lowe SW, Bodis S, MoClateney A, et al. p53 status and efficacy of cancer therapy in vivo. Science 1994;266:807-810 https://doi.org/10.1126/science.7973635
  51. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiationinduced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557 https://doi.org/10.1038/377552a0
  52. Lowe SW, Bodis S, McClatchy A, et al. p53 status and efficacy of cancer therapy in vivo. Science 1994;266:807-810 https://doi.org/10.1126/science.7973635